The Guidelines Caught Up. The Denial Letter Did Not.

Four medical societies (ESSKA with ICRS, the AAOS, the AAPM&R and ASIPP) published formal guidance on PRP and orthobiologics. It supports PRP for knee arthritis at grade 3 or below. It grades each spine target on its own. And it puts diagnosis before any injection.

Between 2024 and 2026, those professional bodies did something that quietly changes how an injury case with orthobiologics gets argued. They wrote the standard down.

ESSKA and the International Cartilage Regeneration and Joint Preservation Society published a formal consensus on platelet-rich plasma for knee osteoarthritis. The American Academy of Orthopaedic Surgeons published a technology overview built on a systematic review. The American Academy of Physical Medicine and Rehabilitation issued a guidance statement in 2026. The American Society of Interventional Pain Physicians published a 119-page practice guideline on regenerative therapies for chronic low back pain. It has 19 recommendations, and the consensus panel agreed on every one at 100%.

None of that is advertising. It is a paper trail. A claim is made of paper trails.

What now exists, and how each document was built

The method matters more than the conclusion. That is because the method is what a defense expert has to attack.

• ESSKA-ICRS consensus, 2024. Built with the RAND/UCLA Appropriateness Method. A panel rated 216 defined clinical scenarios. They crossed age, grade of arthritis, compartment, effusion (fluid in the joint), and what had already been tried.
• ESSKA-ORBIT consensus, 2024. Twenty-eight question-and-statement sets on blood-derived products. Each one carries a letter grade, from A (high-level scientific support) down to D (expert opinion). A separate panel then rated how much it agreed.
• AAOS Technology Overview, 2024. A systematic review that found 54 articles, 36 of them high quality, on PRP for knee osteoarthritis. It weighed PRP against every common option. Those were saline, corticosteroid, hyaluronic acid, exercise, and bone marrow concentrate.
• AAPM&R guidance statement, 2026. A technical expert panel and a modified Delphi process (rounds of expert voting). It was built on a structured literature review updated through June 2025. It produced five evidence-based recommendations and eleven consensus-based best practices.
• ASIPP guidelines, 2025 update. Thirty-five authors, GRADE methodology, and evidence levels for each lumbar spine indication.
• Multispecialty chronic pain guidelines, 2024. Sixteen questions graded against United States Preventive Services Task Force criteria. They span tendinopathy (tendon), muscle, joint, disc, and neuropathic (nerve pain) uses.

Professional societies do not hold panels, run Delphi rounds and publish appropriateness tables for treatments they see as odd side bets. They do it when a treatment is in wide clinical use. The profession then needs to say where it belongs and where it does not.

Is PRP recommended for knee arthritis?

The ESSKA-ORBIT panel issued three grade A statements — its highest evidence tier. There is enough preclinical and clinical evidence to support PRP use in knee osteoarthritis. Clinical evidence shows it works in mild to moderate disease, Kellgren-Lawrence grade 3 or below. And PRP gives a longer effect than the short-lived effect of corticosteroid injection, with a safer profile. That last statement drew the strongest agreement of the whole document.

The ESSKA-ICRS panel went finer. Of its 216 scenarios, 38.9% were rated appropriate, 4.2% inappropriate, and 56.9% uncertain. The strongest consensus was for PRP after other injection treatments had already failed. In that document, appropriate means a patient aged 80 or under, with grade 0 to 3 arthritis, who has already been through conservative care.

Under the consensus statements sit meta-analyses of randomized trials. Against hyaluronic acid across 18 level-1 studies, PRP gave a 44.7% mean improvement in total WOMAC score, against 12.6%. Leukocyte-poor preparations (low in white blood cells) beat leukocyte-rich ones. A 2024 network meta-analysis found PRP, bone marrow concentrate and hyaluronic acid all beat corticosteroid on pain and function at a minimum of six months. A 2025 meta-analysis found the improvement clinically significant. It also found the gain depended on how much platelet concentration was actually delivered.

What do the guidelines say about PRP for the spine?

ASIPP graded each lumbar indication on its own, and the grades do not swap:

• Intradiscal PRP — Evidence Level III, Fair. Consensus recommendation: Moderate.
• Intradiscal bone marrow aspirate concentrate — Level III, Fair. Moderate.
• Epidural PRP — Level III, Fair. Moderate.
• Facet joint PRP and mesenchymal stem cells — Level IV, Limited. Moderate.
• Sacroiliac joint PRP — Level IV, Limited. Low.

That is not a marketing table. It is a society telling its own members exactly how far the evidence reaches for each target, and where it thins out. The same guideline says regenerative medicine “remains in early stages of clinical validation” and asks for careful optimism. Both halves are true at once. The honest version of this page carries both.

The sentence in these documents that nobody quotes

Every one of them puts the treatment in order. ASIPP states that regenerative therapy follows a thorough diagnostic workup. It runs alongside structured exercise, physical therapy and lifestyle care. The ESSKA-ICRS appropriateness ratings are built on what has already been tried and failed. PRP as a first move, before anything has been diagnosed or tried, is the one thing the knee consensus explicitly declines to endorse.

That is a rule about order, and it is the rule most often broken. Clinics break it when they sell an injection as a product. Claims break it when they arrive with a biologic line item and no diagnostic work in front of it. An injection is not the treatment. It is what makes the treatment possible.

Where the record is thin, because the other side will find it

The evidence is indication-specific, and so is every honest sentence about it.

ASIPP's own table is the clearest example. Intradiscal PRP and bone marrow concentrate sit at Level III, Fair. So does epidural PRP. Facet joint injection sits at Level IV, Limited. So does sacroiliac. Four targets a few inches apart, and four different evidence tiers. A citation earned at one target does not carry to the next one. A defense expert who knows that table will say so.

The 2019 ESSKA meniscus consensus is just as direct. It does not establish biological enhancement as a treatment that improves healing of a repaired meniscus. That is a society declining to endorse an indication. A claim that says otherwise is exposed.

And the reporting itself is uneven. A systematic review of 25 randomized trials in knee osteoarthritis checked them against the orthopedic profession's own minimum reporting checklist. On average, they reported 53.1% of the items. Not one hit 80%. The worst-reported category was activation — a variable that changes what the injectate actually is.

None of that makes the knee and elbow evidence vanish. It means a treatment described only as “PRP” on a bill has not really been described at all. Why the characterization is the treatment.

How do PRP guidelines affect an injury claim?

Two things get argued about medical care in an injury case. Was it necessary? And was its value reasonable? Both are argued from the standard of care as the literature describes it.

Before these documents, an adjuster could treat a biologic injection as an outlier and value it that way. After them, things change. A treatment given for a documented indication that maps onto a published scenario is not an outlier. It is care delivered inside a written standard. The person disputing it has to argue with the society that wrote it. Under oath, in front of someone whose job is to notice. What Daubert asks of that argument.

Coverage is a separate question with a separate answer. Most plans do not pay for these injections, and that is a budgeting decision about what a plan funds across its whole membership — not a finding about whether the treatment works. The difference between not covered and not proven.

How this is actually practiced here

The guidelines describe a sequence. So does the clinic.

Diagnosis comes first, and it is a real diagnosis. That means imaging read against the exam, electrodiagnostic testing where the question is nerve, and diagnostic blocks where the question is which structure carries the signal. A block that wipes out the pain and lets it return on schedule has proven something. A block that does nothing has disproved something cheaply, before anyone injected anything costly into it. How a diagnostic block earns its place.

Then the terrain. These products are autologous — the injectate is made from the patient. So the patient’s biology is the raw material. Systemic inflammation, insulin resistance, poor sleep and nicotine are not side notes here. They are the manufacturing conditions. Why we measure the terrain before we inject.

Then delivery, under ultrasound or fluoroscopic guidance. The preparation is described and recorded. Then function measured at intervals, in numbers, so improvement is a data series and not a memory. And alongside all of it, the unglamorous work: loading the tissue, sleeping, and eating in a way that lowers the inflammatory background. Roughly half of what happens in this practice is behavior. It is the half that decides whether the other half holds.

What should you ask before a PRP injection?

1. What is the diagnosis, and what test established it?
2. Which published guideline or consensus scenario fits my situation, and where does it fall in that document?
3. What is being injected — platelet dose, white cell (leukocyte) content, volume, and is it activated?
4. Under what imaging is it being placed?
5. What measure will tell us at three months whether it worked, and what happens if it did not?
6. What is being done about the biology that will be there tomorrow?

A clinic that can answer those six is working inside a standard. A clinic that cannot is selling a syringe. The record it produces will not survive contact with a defense expert.

Related reading: appealing an insurance denial; see also a rotator cuff tear after a car accident, a knee injury at work, arthritis after an injury and repetitive strain injury.

All orthobiologic care: Our orthobiologics and PRP injections page lists every injury we treat with PRP, bone marrow concentrate and microfragmented fat.

Frequently asked questions

Is PRP still considered an unsettled treatment?

Not by the bodies that write the standards. Between 2024 and 2026, ESSKA and ICRS, the AAOS, AAPM&R and ASIPP all published consensus documents or guidance with graded recommendations. Those grades are specific to each indication, not blanket. Coverage is a separate matter from evidence. Learn more: Not covered is a budget decision, not a verdict on the evidence.

What does Level III, Fair, with a moderate recommendation actually mean?

It is ASIPP’s grading for intradiscal and epidural PRP in chronic low back pain. The supporting studies are mostly observational or lower-tier controlled evidence, graded with GRADE. The panel reached moderate consensus that the treatment has a role in well-chosen patients. It is a measured statement, not a promise. Learn more: What a pain society actually says about injecting an injured disc.

Does a guideline make my treatment automatically defensible in a claim?

No. It makes the argument a medical one instead of a rhetorical one. What carries a claim is the record. A test that established the diagnosis. An indication that maps to a published scenario. The product described. The guidance method named. And function measured over time. Learn more: Write the note like a defense expert will read it.

Is PRP appropriate for every painful joint after a crash?

No. The honest reading of the evidence is that it is specific to each indication. The knee and lateral elbow evidence is comparatively strong. Randomized-trial meta-analyses in Achilles tendinopathy and rotator cuff disorders did not show clinical benefit. A citation earned in one joint does not carry to another. Learn more: What the knee guidelines say, grade by grade.

Why does the clinic test metabolic markers before injecting?

Because the injectate is made from you. Platelet products act on the tissue environment they land in. An environment that stays inflamed and insulin-resistant works against the repair you are paying for. Learn more: Why the terrain comes before the biologic.

Will my health plan pay for this?

Usually not. Most commercial plans and Medicare do not cover orthobiologic injections, and the ASIPP guideline instructs clinicians to tell patients so before treatment. Non-coverage is a decision about what a plan funds, and prior authorization for anything is not a guarantee of payment. Learn more: How coverage and evidence get confused.

Where is Injury Experts located?

Injury Experts is at 4477 Woodson Rd, Suite 202, St. Louis, MO 63134, next to Lambert International Airport, serving the St. Louis region in Missouri and Illinois. Call (314) 887-5866 or text (314) 886-5902.

Key takeaways

• Four societies published graded guidance on orthobiologics between 2024 and 2026. The grades are specific to each indication and do not carry between joints.
• Every one of those documents puts the treatment in order: diagnosis first, conservative care first, biologic after. And it runs alongside exercise, rehab and lifestyle care.
• The evidence is negative in some indications, including Achilles tendinopathy and rotator cuff disorders. That belongs in an honest account.
• Most plans do not pay for these injections. Non-coverage is a budgeting decision, not a finding about whether the treatment works.
• In a claim, the record carries the treatment: the indication mapped to a published scenario, the product described, the placement guided, and function measured.

This article is for general education and is not medical advice. It does not create a physician–patient relationship. Do not start, stop, or change any medication — including opioid medication — without consulting your physician.

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine.